Stephen P. Coburn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stephen P. Coburn has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
J. Dennis Mahuren
3 shared publicationsJacobo Wortsman
3 shared publications- Fan Zhang
Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children - St. Louis, St. Louis, MO 63110, USA
2 shared publications J.Dennis Mahuren
2 shared publications- Karen L. Ericson
Department of Chemistry, Indiana University-Purdue University, Fort Wayne, IN 46805, USA
2 shared publications - Michael P. Whyte
Division of Bone and Mineral Diseases, Department of Internal Medicine, Washington University School of Medicine, St Louis, MO 63110, USA; Center for Metabolic Bone Disease and Molecular Research, Shriners Hospitals for Children-St. Louis, St. Louis, MO 63110, USA
2 shared publications
Latest Publications
- 28 April 2021
- Published by Taylor & Francis
- p. 61-75
Animal and Mathematical Models of Vitamin B-6 Metabolism
For a variety of reasons it is often inconvenient or impossible to conduct certain types of research in humans. One possibility is to study intact animals of other species. Another possibility is to examine the metabolism of isolated organs, tissues or cells. A third approach is to use mathematical models. Two major factors which should be considered in selecting an animal model of human metabolism are physiology and biochemistry. The chapter suggests that the best animal models for human metabolism of vitamin B-6 are the guinea pig, pig, and monkeys. Mathematical modeling provides a mechanism for correlating kinetic data to metabolic processes. The earliest attempts to model vitamin B-6 metabolism were single-dose tracer studies. The pattern of urinary excretion of isotope could be explained most simply by a small pool with high turnover in equilibrium with a large pool with slow turnover.
- 28 April 2021
- Published by Taylor & Francis
- p. 61-75
Animal and Mathematical Models of Vitamin B-6 Metabolism
For a variety of reasons it is often inconvenient or impossible to conduct certain types of research in humans. One possibility is to study intact animals of other species. Another possibility is to examine the metabolism of isolated organs, tissues or cells. A third approach is to use mathematical models. Two major factors which should be considered in selecting an animal model of human metabolism are physiology and biochemistry. The chapter suggests that the best animal models for human metabolism of vitamin B-6 are the guinea pig, pig, and monkeys. Mathematical modeling provides a mechanism for correlating kinetic data to metabolic processes. The earliest attempts to model vitamin B-6 metabolism were single-dose tracer studies. The pattern of urinary excretion of isotope could be explained most simply by a small pool with high turnover in equilibrium with a large pool with slow turnover.
- 29 July 2015
- Published by Springer Nature
- Vol. 76, 207-238
Vitamin B-6 Metabolism and Interactions with TNAP
Two observations stimulated the interest in vitamin B-6 and alkaline phosphatase in brain: the marked increase in plasma pyridoxal phosphate and the occurrence of pyridoxine responsive seizures in hypophosphatasia. The increase in plasma pyridoxal phosphate indicates the importance of tissue non-specific alkaline phosphatase (TNAP) in transferring vitamin B-6 into the tissues. Vitamin B-6 is involved in the biosynthesis of most of the neurotransmitters. Decreased gamma-aminobutyrate (GABA) appears to be most directly related to the development of seizures in vitamin B-6 deficiency. Cytosolic pyridoxal phosphatase/chronophin may interact with vitamin B-6 metabolism and neuronal development and function. Ethanolaminephosphate phospholyase interacts with phosphoethanolamine metabolism. Extracellular pyridoxal phosphate may interact with purinoceptors and calcium channels. In conclusion, TNAP clearly influences extracellular and intracellular metabolism of vitamin B-6 in brain, particularly during developmental stages. While effects on GABA metabolism appear to be the major contributor to seizures, multiple other intra- and extra-cellular metabolic systems may be affected directly and/or indirectly by altered vitamin B-6 hydrolysis and uptake resulting from variations in alkaline phosphatase activity.
- 29 July 2015
- Published by Springer Nature
- Vol. 76, 207-238
Vitamin B-6 Metabolism and Interactions with TNAP
Two observations stimulated the interest in vitamin B-6 and alkaline phosphatase in brain: the marked increase in plasma pyridoxal phosphate and the occurrence of pyridoxine responsive seizures in hypophosphatasia. The increase in plasma pyridoxal phosphate indicates the importance of tissue non-specific alkaline phosphatase (TNAP) in transferring vitamin B-6 into the tissues. Vitamin B-6 is involved in the biosynthesis of most of the neurotransmitters. Decreased gamma-aminobutyrate (GABA) appears to be most directly related to the development of seizures in vitamin B-6 deficiency. Cytosolic pyridoxal phosphatase/chronophin may interact with vitamin B-6 metabolism and neuronal development and function. Ethanolaminephosphate phospholyase interacts with phosphoethanolamine metabolism. Extracellular pyridoxal phosphate may interact with purinoceptors and calcium channels. In conclusion, TNAP clearly influences extracellular and intracellular metabolism of vitamin B-6 in brain, particularly during developmental stages. While effects on GABA metabolism appear to be the major contributor to seizures, multiple other intra- and extra-cellular metabolic systems may be affected directly and/or indirectly by altered vitamin B-6 hydrolysis and uptake resulting from variations in alkaline phosphatase activity.
- Top Cited Papers
Hypophosphatasia: Validation and expansion of the clinical nosology for children from 25years experience with 173 pediatric patients
- 1 February 2003
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (2) , 292-300
Cutaneous Metabolism of Vitamin B-6
- 1 February 2003
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 120 (2) , 292-300
Cutaneous Metabolism of Vitamin B-6
- 1 January 2003
- Published by Springer Nature
- Vol. 537, 173-192
Modeling Short (7 hour)- and Long (6 week)-Term Kinetics of Vitamin B-6 Metabolism with Stable Isotopes in Humans
- 1 January 2003
- Published by Springer Nature
- Vol. 537, 173-192
Modeling Short (7 hour)- and Long (6 week)-Term Kinetics of Vitamin B-6 Metabolism with Stable Isotopes in Humans
- Open Access
- 1 January 2002
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 75 (1) , 57-64
Elevated plasma 4-pyridoxic acid in renal insufficiency
Background: Renal insufficiency is associated with altered vitamin B-6 metabolism. We have observed high concentrations of 4-pyridoxic acid, the major catabolite of vitamin B-6 metabolism, in plasma during renal insufficiency. Objective: The objective was to evaluate the renal handling of 4-pyridoxic acid and the effects of renal dysfunction on vitamin B-6 metabolism. Design: We measured the renal clearance of 4-pyridoxic acid and creatinine in 17 nonpregnant, 17 pregnant, and 16 lactating women. We then examined the influence of vitamin B-6 or alkaline phosphatase activity on the ratio of 4-pyridoxic acid to pyridoxal (PA:PL) in plasma in 10 men receiving a low (0.4 mg pyridoxine·HCl/d) or high (200 mg pyridoxine·HCl/d) vitamin B-6 intake for 6 wk, in 10 healthy subjects during a 21-d fast, in 1235 plasma samples from 799 people screened for hypophosphatasia, and in 67 subjects with a range of serum creatinine concentrations. Results: Renal clearance of 4-pyridoxic acid was 232 ± 94 mL/min in nonpregnant women, 337 ± 140 mL/min in pregnant women, and 215 ± 103 mL/min in lactating healthy women. These values were approximately twice the creatinine clearance, indicating that 4-pyridoxic acid is at least partially eliminated by tubular secretion. Elevated plasma creatinine concentrations were associated with marked elevations in 4-pyridoxic acid and PA:PL. PA:PL was not affected by wide variations in vitamin B-6 intake or by the wide range of pyridoxal-P concentrations encountered while screening for hypophosphatasia. Conclusions: Plasma 4-pyridoxic acid concentrations are markedly elevated in renal insufficiency. Plasma PA:PL can distinguish between increases in 4-pyridoxic acid concentrations due to increased dietary intake and those due to renal insufficiency.
- 1 January 2002
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 75 (1) , 57-64
Open AccessElevated plasma 4-pyridoxic acid in renal insufficiency
Background: Renal insufficiency is associated with altered vitamin B-6 metabolism. We have observed high concentrations of 4-pyridoxic acid, the major catabolite of vitamin B-6 metabolism, in plasma during renal insufficiency. Objective: The objective was to evaluate the renal handling of 4-pyridoxic acid and the effects of renal dysfunction on vitamin B-6 metabolism. Design: We measured the renal clearance of 4-pyridoxic acid and creatinine in 17 nonpregnant, 17 pregnant, and 16 lactating women. We then examined the influence of vitamin B-6 or alkaline phosphatase activity on the ratio of 4-pyridoxic acid to pyridoxal (PA:PL) in plasma in 10 men receiving a low (0.4 mg pyridoxine·HCl/d) or high (200 mg pyridoxine·HCl/d) vitamin B-6 intake for 6 wk, in 10 healthy subjects during a 21-d fast, in 1235 plasma samples from 799 people screened for hypophosphatasia, and in 67 subjects with a range of serum creatinine concentrations. Results: Renal clearance of 4-pyridoxic acid was 232 ± 94 mL/min in nonpregnant women, 337 ± 140 mL/min in pregnant women, and 215 ± 103 mL/min in lactating healthy women. These values were approximately twice the creatinine clearance, indicating that 4-pyridoxic acid is at least partially eliminated by tubular secretion. Elevated plasma creatinine concentrations were associated with marked elevations in 4-pyridoxic acid and PA:PL. PA:PL was not affected by wide variations in vitamin B-6 intake or by the wide range of pyridoxal-P concentrations encountered while screening for hypophosphatasia. Conclusions: Plasma 4-pyridoxic acid concentrations are markedly elevated in renal insufficiency. Plasma PA:PL can distinguish between increases in 4-pyridoxic acid concentrations due to increased dietary intake and those due to renal insufficiency.
- 1 January 2002
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 39 (1) , 134-145
Vitamin B6 metabolism and homocysteine in end-stage renal disease and chronic renal insufficiency
- 1 January 2002
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 39 (1) , 134-145
Vitamin B6 metabolism and homocysteine in end-stage renal disease and chronic renal insufficiency
- 1 November 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (11) , 3951-3957
Alkaline Phosphatase (EC 3.1.3.1) in Serum Is Inhibited by Physiological Concentrations of Inorganic Phosphate1
Natural and artificial manipulation of tissue nonspecific alkaline phosphatase activity indicates that pyrophosphate, phosphoethanolamine, and pyridoxal 5'-phosphate are among the natural substrates for this enzyme. Although inorganic phosphate has been recognized as a competitive inhibitor of this enzyme for many years, the influence of phosphate on alkaline phosphatase activity in serum under physiological conditions has not been previously reported. We examined the kinetics of tissue nonspecific alkaline phosphatase from bovine kidney and sera from 49 patients with a wide range of endogenous phosphate concentrations using pyridoxine 5'-phosphate as a substrate at pH 7.4. For the bovine kidney enzyme, the Km was 0.42 +/- 0.04 micromol/L, and the Ki for phosphate was 2.4 +/- 0.2 micromol/L. Analysis of the kinetics using pyridoxine 5'-phosphate in undiluted serum from 10 subjects with phosphorus ranging from 0.5-2.1 mmol/L and alkaline phosphatase activity ranging from 41-165 nmol/min x mL gave estimates for the Km of 56 +/- 11 micromol/L and for the Ki of 540 +/- 82 micromol/L for phosphate. This indicates that under physiological conditions alkaline phosphatase activity toward pyridoxine 5'-phosphate is reduced approximately 50% by the normal phosphate concentration and that it will increase or decrease significantly in response to changes in phosphate concentration within the ranges observed clinically.
- 1 November 1998
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 83 (11) , 3951-3957
Alkaline Phosphatase (EC 3.1.3.1) in Serum Is Inhibited by Physiological Concentrations of Inorganic Phosphate1
Natural and artificial manipulation of tissue nonspecific alkaline phosphatase activity indicates that pyrophosphate, phosphoethanolamine, and pyridoxal 5'-phosphate are among the natural substrates for this enzyme. Although inorganic phosphate has been recognized as a competitive inhibitor of this enzyme for many years, the influence of phosphate on alkaline phosphatase activity in serum under physiological conditions has not been previously reported. We examined the kinetics of tissue nonspecific alkaline phosphatase from bovine kidney and sera from 49 patients with a wide range of endogenous phosphate concentrations using pyridoxine 5'-phosphate as a substrate at pH 7.4. For the bovine kidney enzyme, the Km was 0.42 +/- 0.04 micromol/L, and the Ki for phosphate was 2.4 +/- 0.2 micromol/L. Analysis of the kinetics using pyridoxine 5'-phosphate in undiluted serum from 10 subjects with phosphorus ranging from 0.5-2.1 mmol/L and alkaline phosphatase activity ranging from 41-165 nmol/min x mL gave estimates for the Km of 56 +/- 11 micromol/L and for the Ki of 540 +/- 82 micromol/L for phosphate. This indicates that under physiological conditions alkaline phosphatase activity toward pyridoxine 5'-phosphate is reduced approximately 50% by the normal phosphate concentration and that it will increase or decrease significantly in response to changes in phosphate concentration within the ranges observed clinically.
- 1 January 1996
- Published by Elsevier
Mathematical Modeling in Experimental Nutrition - Vitamins, Proteins, Methods
- 1 January 1996
- Published by Elsevier
Mathematical Modeling in Experimental Nutrition - Vitamins, Proteins, Methods